Annual CFF
-$1.79 B
+$122.00 M+6.38%
December 31, 2024
Summary
- As of February 6, 2025, TEVA annual cash flow from financing activities is -$1.79 billion, with the most recent change of +$122.00 million (+6.38%) on December 31, 2024.
- During the last 3 years, TEVA annual CFF has risen by +$381.00 million (+17.54%).
- TEVA annual CFF is now -107.10% below its all-time high of $25.22 billion, reached on December 31, 2016.
Performance
TEVA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$674.00 M
-$674.00 M-100.00%
December 31, 2024
Summary
- As of February 6, 2025, TEVA quarterly cash flow from financing activities is -$674.00 million, with the most recent change of -$674.00 million (-100.00%) on December 31, 2024.
- Over the past year, TEVA quarterly CFF has dropped by -$523.00 million (-346.36%).
- TEVA quarterly CFF is now -102.66% below its all-time high of $25.37 billion, reached on September 30, 2016.
Performance
TEVA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$1.79 B
-$98.00 M-5.79%
December 31, 2024
Summary
- As of February 6, 2025, TEVA TTM cash flow from financing activities is -$1.79 billion, with the most recent change of -$98.00 million (-5.79%) on December 31, 2024.
- Over the past year, TEVA TTM CFF has dropped by -$433.00 million (-31.89%).
- TEVA TTM CFF is now -105.85% below its all-time high of $30.63 billion, reached on September 30, 2016.
Performance
TEVA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TEVA Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +6.4% | -346.4% | -31.9% |
3 y3 years | +17.5% | -99.4% | +11.1% |
5 y5 years | +7.0% | -439.2% | +5.0% |
TEVA Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -20.4% | +17.5% | <-9999.0% | +30.2% | -40.3% | +21.1% |
5 y | 5-year | -20.4% | +17.5% | <-9999.0% | +42.7% | -40.3% | +26.5% |
alltime | all time | -107.1% | +68.8% | -102.7% | +73.1% | -105.8% | +70.5% |
Teva Pharmaceutical Industries Limited Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | -$1.79 B(-6.4%) | -$674.00 M(<-9900.0%) | -$1.79 B(+5.8%) |
Sep 2024 | - | $0.00(-100.0%) | -$1.69 B(-25.4%) |
Jun 2024 | - | -$966.00 M(+539.7%) | -$2.27 B(+67.1%) |
Mar 2024 | - | -$151.00 M(-73.8%) | -$1.36 B(-29.0%) |
Dec 2023 | -$1.91 B(+28.6%) | -$576.00 M(0.0%) | -$1.91 B(-6.6%) |
Sep 2023 | - | -$576.00 M(+947.3%) | -$2.05 B(+7.1%) |
Jun 2023 | - | -$55.00 M(-92.2%) | -$1.91 B(-12.9%) |
Mar 2023 | - | -$706.00 M(-0.7%) | -$2.19 B(+47.6%) |
Dec 2022 | -$1.49 B(-31.5%) | -$711.00 M(+61.6%) | -$1.49 B(+16.4%) |
Sep 2022 | - | -$440.00 M(+30.2%) | -$1.28 B(-36.6%) |
Jun 2022 | - | -$338.00 M(<-9900.0%) | -$2.01 B(+20.1%) |
Mar 2022 | - | $2.00 M(-100.4%) | -$1.68 B(-22.8%) |
Dec 2021 | -$2.17 B(+15.2%) | -$501.00 M(-57.4%) | -$2.17 B(+20.9%) |
Sep 2021 | - | -$1.18 B(>+9900.0%) | -$1.80 B(+7.2%) |
Jun 2021 | - | -$1.00 M(-99.8%) | -$1.68 B(-0.1%) |
Mar 2021 | - | -$493.00 M(+294.4%) | -$1.68 B(-11.0%) |
Dec 2020 | -$1.89 B(-2.1%) | -$125.00 M(-88.2%) | -$1.89 B(-5.8%) |
Sep 2020 | - | -$1.06 B(>+9900.0%) | -$2.00 B(-16.8%) |
Jun 2020 | - | -$3.00 M(-99.6%) | -$2.40 B(-1.3%) |
Mar 2020 | - | -$700.00 M(+190.5%) | -$2.44 B(+26.5%) |
Dec 2019 | -$1.93 B(-42.5%) | -$241.00 M(-83.5%) | -$1.93 B(-11.8%) |
Sep 2019 | - | -$1.46 B(+4074.3%) | -$2.18 B(+52.9%) |
Jun 2019 | - | -$35.00 M(-81.5%) | -$1.43 B(-1.4%) |
Mar 2019 | - | -$189.00 M(-62.1%) | -$1.45 B(-56.8%) |
Dec 2018 | -$3.35 B(-41.7%) | -$499.00 M(-29.2%) | -$3.35 B(-37.5%) |
Sep 2018 | - | -$705.00 M(+1158.9%) | -$5.36 B(-2.2%) |
Jun 2018 | - | -$56.00 M(-97.3%) | -$5.48 B(-9.8%) |
Mar 2018 | - | -$2.09 B(-16.6%) | -$6.07 B(+5.6%) |
Dec 2017 | -$5.75 B(-122.8%) | -$2.51 B(+203.8%) | -$5.75 B(+45.8%) |
Sep 2017 | - | -$825.00 M(+26.7%) | -$3.94 B(-117.7%) |
Jun 2017 | - | -$651.00 M(-63.2%) | $22.25 B(-4.0%) |
Mar 2017 | - | -$1.77 B(+152.2%) | $23.18 B(-8.1%) |
Dec 2016 | $25.22 B(+424.8%) | -$701.00 M(-102.8%) | $25.22 B(-17.7%) |
Sep 2016 | - | $25.37 B(+8993.9%) | $30.63 B(+634.4%) |
Jun 2016 | - | $279.00 M(+4.5%) | $4.17 B(-16.2%) |
Mar 2016 | - | $267.00 M(-94.3%) | $4.98 B(+3.6%) |
Dec 2015 | $4.80 B(-302.3%) | $4.71 B(-532.6%) | $4.80 B(-1055.3%) |
Sep 2015 | - | -$1.09 B(-200.3%) | -$503.00 M(-295.0%) |
Jun 2015 | - | $1.09 B(+1068.8%) | $258.00 M(-115.7%) |
Mar 2015 | - | $93.00 M(-115.7%) | -$1.65 B(-30.6%) |
Dec 2014 | -$2.38 B(-38.8%) | -$593.00 M(+80.2%) | -$2.38 B(-1.1%) |
Sep 2014 | - | -$329.00 M(-59.8%) | -$2.40 B(+3.1%) |
Jun 2014 | - | -$819.00 M(+29.2%) | -$2.33 B(+3.1%) |
Mar 2014 | - | -$634.00 M(+2.4%) | -$2.26 B(-41.9%) |
Dec 2013 | -$3.88 B(+131.4%) | -$619.00 M(+141.8%) | -$3.88 B(+29.5%) |
Sep 2013 | - | -$256.00 M(-65.8%) | -$3.00 B(-9.5%) |
Jun 2013 | - | -$748.00 M(-66.9%) | -$3.31 B(-0.4%) |
Mar 2013 | - | -$2.26 B(-949.6%) | -$3.33 B(+98.2%) |
Dec 2012 | -$1.68 B(-150.3%) | $266.00 M(-146.7%) | -$1.68 B(-178.1%) |
Sep 2012 | - | -$570.00 M(-25.1%) | $2.15 B(-37.1%) |
Jun 2012 | - | -$761.00 M(+24.1%) | $3.42 B(-2.2%) |
Mar 2012 | - | -$613.00 M(-115.0%) | $3.49 B(+4.7%) |
Dec 2011 | $3.34 B | $4.09 B(+486.2%) | $3.34 B(-351.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2011 | - | $698.00 M(-202.0%) | -$1.33 B(-40.4%) |
Jun 2011 | - | -$684.00 M(-11.2%) | -$2.23 B(>+9900.0%) |
Mar 2011 | - | -$770.00 M(+34.4%) | -$22.00 M(-103.8%) |
Dec 2010 | $573.00 M(-125.3%) | -$573.00 M(+180.9%) | $573.00 M(-38.6%) |
Sep 2010 | - | -$204.00 M(-113.4%) | $933.00 M(+288.8%) |
Jun 2010 | - | $1.52 B(-971.4%) | $240.00 M(-109.9%) |
Mar 2010 | - | -$175.00 M(-17.8%) | -$2.42 B(+6.7%) |
Dec 2009 | -$2.27 B(-266.8%) | -$213.00 M(-76.3%) | -$2.27 B(+2444.9%) |
Sep 2009 | - | -$897.00 M(-20.7%) | -$89.00 M(-112.3%) |
Jun 2009 | - | -$1.13 B(+4612.5%) | $724.00 M(-40.8%) |
Mar 2009 | - | -$24.00 M(-101.2%) | $1.22 B(-10.0%) |
Dec 2008 | $1.36 B(-475.1%) | $1.96 B(-2436.9%) | $1.36 B(-278.4%) |
Sep 2008 | - | -$84.00 M(-86.7%) | -$761.00 M(-17.3%) |
Jun 2008 | - | -$633.00 M(-665.2%) | -$920.00 M(+221.7%) |
Mar 2008 | - | $112.00 M(-171.8%) | -$286.00 M(-21.0%) |
Dec 2007 | -$362.00 M(-117.9%) | -$156.00 M(-35.8%) | -$362.00 M(-31.9%) |
Sep 2007 | - | -$243.00 M(<-9900.0%) | -$531.30 M(-1.9%) |
Jun 2007 | - | $1.00 M(-97.2%) | -$541.80 M(+3.2%) |
Mar 2007 | - | $36.00 M(-111.1%) | -$525.00 M(-125.9%) |
Dec 2006 | $2.02 B(-746.6%) | -$325.30 M(+28.3%) | $2.02 B(-25.0%) |
Sep 2006 | - | -$253.50 M(-1524.2%) | $2.70 B(-3.5%) |
Jun 2006 | - | $17.80 M(-99.3%) | $2.80 B(+8.3%) |
Mar 2006 | - | $2.58 B(+636.9%) | $2.58 B(-924.8%) |
Dec 2005 | -$313.00 M(-136.7%) | $350.80 M(-323.9%) | -$313.00 M(-59.1%) |
Sep 2005 | - | -$156.70 M(-20.6%) | -$764.40 M(+6.9%) |
Jun 2005 | - | -$197.40 M(-36.3%) | -$714.80 M(+31.2%) |
Mar 2005 | - | -$309.70 M(+207.9%) | -$544.80 M(-163.9%) |
Dec 2004 | $852.00 M(+2778.4%) | -$100.60 M(-6.1%) | $852.00 M(-13.6%) |
Sep 2004 | - | -$107.10 M(+290.9%) | $986.60 M(-8.7%) |
Jun 2004 | - | -$27.40 M(-102.5%) | $1.08 B(-2.5%) |
Mar 2004 | - | $1.09 B(+3097.4%) | $1.11 B(+3643.6%) |
Dec 2003 | $29.60 M(-91.2%) | $34.00 M(-361.5%) | $29.60 M(-93.1%) |
Sep 2003 | - | -$13.00 M(<-9900.0%) | $428.20 M(+0.8%) |
Jun 2003 | - | $0.00(-100.0%) | $424.70 M(+7.4%) |
Mar 2003 | - | $8.60 M(-98.0%) | $395.50 M(+17.2%) |
Dec 2002 | $337.50 M(+26.5%) | $432.60 M(-2721.8%) | $337.50 M(-409.7%) |
Sep 2002 | - | -$16.50 M(-43.5%) | -$108.98 M(-131.5%) |
Jun 2002 | - | -$29.20 M(-40.9%) | $345.47 M(+1.9%) |
Mar 2002 | - | -$49.40 M(+255.8%) | $339.11 M(+27.1%) |
Dec 2001 | $266.72 M(+0.4%) | -$13.88 M(-103.2%) | $266.72 M(-4.9%) |
Sep 2001 | - | $437.95 M(-1331.5%) | $280.60 M(-278.3%) |
Jun 2001 | - | -$35.56 M(-70.8%) | -$157.35 M(+29.2%) |
Mar 2001 | - | -$121.79 M | -$121.79 M |
Dec 2000 | $265.71 M(+75.4%) | - | - |
Dec 1999 | $151.48 M(+174.6%) | - | - |
Dec 1998 | $55.16 M(-141.0%) | - | - |
Dec 1997 | -$134.50 M(-202.5%) | - | - |
Dec 1996 | $131.20 M(+226.4%) | - | - |
Dec 1995 | $40.20 M(+0.8%) | - | - |
Dec 1994 | $39.90 M(-10.5%) | - | - |
Dec 1993 | $44.60 M(+85.8%) | - | - |
Dec 1992 | $24.00 M(-31.8%) | - | - |
Dec 1991 | $35.20 M | - | - |
FAQ
- What is Teva Pharmaceutical Industries Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited annual CFF year-on-year change?
- What is Teva Pharmaceutical Industries Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited quarterly CFF year-on-year change?
- What is Teva Pharmaceutical Industries Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited TTM CFF year-on-year change?
What is Teva Pharmaceutical Industries Limited annual cash flow from financing activities?
The current annual CFF of TEVA is -$1.79 B
What is the all time high annual CFF for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high annual cash flow from financing activities is $25.22 B
What is Teva Pharmaceutical Industries Limited annual CFF year-on-year change?
Over the past year, TEVA annual cash flow from financing activities has changed by +$122.00 M (+6.38%)
What is Teva Pharmaceutical Industries Limited quarterly cash flow from financing activities?
The current quarterly CFF of TEVA is -$674.00 M
What is the all time high quarterly CFF for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high quarterly cash flow from financing activities is $25.37 B
What is Teva Pharmaceutical Industries Limited quarterly CFF year-on-year change?
Over the past year, TEVA quarterly cash flow from financing activities has changed by -$523.00 M (-346.36%)
What is Teva Pharmaceutical Industries Limited TTM cash flow from financing activities?
The current TTM CFF of TEVA is -$1.79 B
What is the all time high TTM CFF for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high TTM cash flow from financing activities is $30.63 B
What is Teva Pharmaceutical Industries Limited TTM CFF year-on-year change?
Over the past year, TEVA TTM cash flow from financing activities has changed by -$433.00 M (-31.89%)